WINNIPEG, MANITOBA--(Marketwire - April 03, 2008) - Medicure Inc. (TSX: MPH)(AMEX: MCU), a cardiovascular-focused biopharmaceutical company, today commented on the positive results of two large AGGRASTAT® (tirofiban) studies, MULTI-STRATEGY 2 and ON-TIME 2, that were presented at the Late Breaking Sessions of the American College of Cardiology 57th Annual Scientific Session.
